Pre-ablation rate control therapy and direct-to-catheter ablation in patients with persistent atrial fibrillation: A DECAAF II subanalysis
Prior treatment with diltiazem or metoprolol before ablation of PersAF did not show additional benefits in reducing patient outcomes such as AF recurrence, fibrosis, or improving QoL.
Authors
- Amitabh C. Pandey (ORCID: https://orcid.org/0000-0002-1541-7023)
- Hadi Younes (ORCID: https://orcid.org/0000-0002-7202-1164)
- Radia Ksayer
- Alina Upreti
- Ghassan Bidaoui (ORCID: https://orcid.org/0000-0002-3562-7386)
- Eli Tsakiris (ORCID: https://orcid.org/0009-0003-2542-941X)
- Han Feng
- Christian M. Massad (ORCID: https://orcid.org/0009-0002-3441-0617)
- Bella Gonzalez Perez
- Nassir F. Marrouche
- Yishi Jia
Institutions
- Tulane University (US)
Publication Details
- Journal
- Journal of Interventional Cardiac Electrophysiology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1007/s10840-025-02218-1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00